TVTX News and Press, Travere Therapeutics Inc.

2026-07-07 10:28:30 ET Biotech M&A has been scorching hot this year. Big Pharma spent approximately $106 billion on 201 acquisitions in the first half of 2026. If this pace continues, the industry is expected to close more than $250 billion in deal value , placing this as th...

2026-07-03 04:37:04 ET In the long term, I believe Travere Therapeutics ( TVTX ) will likely continue to grow as it develops a presence in other rare kidney disease markets. Thus, the company will have a solid platform upon which to expand its business beyond IgA nephropathy in both...

2026-06-29 17:20:00 ET A week ago, I wrote that leadership had left the mega-cap “generals” and split into two baskets: semiconductors (velocity) and regional banks (breadth). That’s still true. But the dashboard has been quietly flagging a third group climbing the ...

William Rote, Ph.D., chief research officer plans to retire in early 2027 Jula Inrig, M.D., to be named executive vice president, head of research and development and CMO, expanding her responsibilities to include the Company’s research organization Travere Therapeutics...

2026-06-08 13:08:31 ET Travere Therapeutics, Inc. (TVTX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 8, 2026 11:20 AM EDT... Read the full article on Seeking Alpha For further details see: Travere Therapeutics, Inc. (TVTX) Presents at Goldman Sachs 47th ...

Patients in the study who initiated and remained on FILSPARI maintained durable and deepened proteinuria reductions, resulting in further achievement of clinically meaningful low proteinuria thresholds over time Patients who transitioned from active control maximum labeled dose irbesartan...

2026-06-03 14:15:03 ET Citigroup analyst issues BUY recommendation for TVTX on June 3, 2026 05:01PM ET. The previous analyst recommendation was Buy. TVTX was trading at $44.868 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...

2026-06-02 16:10:00 ET The biotech sector has made significant strides in recent years, and the market's volatility can increase the appeal of biotech ETFs. Even with a good understanding of the system, no one can predict which treatment, device or therapy will give the biggest ...

2026-06-02 11:32:14 ET Travere Therapeutics, Inc. (TVTX) Discusses Exclusive Licensing and Collaboration Agreement for Seborbrutinib with Everest Medicines June 2, 2026 8:30 AM EDT... Read the full article on Seeking Alpha For further details see: Travere Therapeutics, Inc. ...

2026-06-02 08:07:58 ET More on Travere Therapeutics Travere Therapeutics, Inc. (TVTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript Travere Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation Travere Therapeutics, Inc. (TVTX) ...